Login / Signup

Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET).

Seong-Jang KimMin-Young ParkKyoungjune PakJun Hee HanGun-Wook KimHoon-Soo KimHyun-Chang KoMoon-Bum KimByung-Soo Kim
Published in: The Journal of dermatological treatment (2018)
Patients with moderate-to-severe psoriasis are at an increased risk for depressive symptoms, and treatment with ustekinumab may be beneficial. FDG-PET does not reflect the changes in depressive symptoms in such patients.
Keyphrases